Endocrine Abstracts

The introduction of chemical and genetically modified short and long acting insulin molecules, as well as mixed insulin preparations, has provided novel tools to improve glycaemic regulation in patients with diabetes. Reaching the glycaemic target of an HbA1c below 7% represent a major challenge in many patients with type 2 diabetes. Different insulin preparations can be used in various different combinations with a variable number of daily injections as well as in different c...

Follistatin is a hepatokine found to be elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. We report that elevated baseline circulating follistatin levels predict future T2D incidence in longitudinal cohorts including up to 5274 individuals. Individuals with elevated circulating follistatin had higher risk of developing type 2 diabetes during follow-up of 4 years (IMI-DIRECT-METSIM, n = 1079, Finland), 5 and 19 years (MDC-CC, n...